RestorGenex Corporation (OTCQB: RESX) is a specialty biopharmaceutical company focused on developing a platform of therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. The company’s lead product is a PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The company is also working on an anti-androgen compound for the treatment of acne vulgaris. For more information, visit the company’s website at www.restorgenex.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.